Skip to content
OpenCapital
Get started

Oric Pharmaceuticals, Inc. ORIC Payment Of Deferred Issuance Costs

Other financials

Income statement

See full
Operating income-$39.6M-21.1%
Net income-$35.8M-19.1%
EPS (diluted)-$0.34+19.0%

Balance sheet

See full
Cash & equivalents$56.4M+14.3%
Total debt$3.3M+2.6%
Total equity$415.6M+89.1%
Total assets$436.8M+79.8%

Cash flow

See full
Operating cash flow-$32.4M+0.3%
CapEx$2.0K-99.5%
Free cash flow-$32.4M+1.5%

Valuation

See full
Market cap$976.17M+23.4%
Enterprise value$923.07M+23.9%

Returns & leverage

See full
Return on equity-42.6%-4.6pp
Debt / equity0×0.0×
Current ratio16.3×+4.3×

Where this comes from

Reported directly by Oric Pharmaceuticals, Inc. in its filing.

Tagged under the XBRL concept oric:PaymentOfDeferredIssuanceCosts.

The official record: Oric Pharmaceuticals, Inc.’s 10-Q, filed May 4, 2026, on SEC EDGAR. View the filing →

Ask your AI about Oric Pharmaceuticals, Inc.'s payment of deferred issuance costs.

Connect your AI assistant and see it in context, right in your chat.

Connect your AI
Harbor at dusk
Claude

Questions, answered.

What is Oric Pharmaceuticals, Inc.'s payment of deferred issuance costs?
Oric Pharmaceuticals, Inc. (ORIC) reported payment of deferred issuance costs of -$242K in Q1 2025.